Moderna’s Melanoma Breakthrough | Sacramento News

Sacramento News Today | 2 Min News | The Daily News Now! · Aug 19, 2026 · 1m

Moderna’s stock soared more than double after revealing breakthrough results from an experimental mRNA melanoma vaccine, intismeran — designed to use a patient’s own cancer cells — which, when paired with Merck’s Keytruda, significantly reduced recurrence and metastasis in post-surgery patients. Called a “landmark moment” by researchers, this personalized cancer therapy could revolutionize melanoma treatment, offering hope for longer remission and earlier intervention. While Moderna’s shares haven’t returned to pandemic-era highs, this milestone marks a major leap forward in mRNA-based…